Ipragliflozin - Astellas Pharma
Alternative Names: ASP-1941; Ipragliflozin L-Proline; SuglatLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Astellas Pharma; Kotobuki Pharmaceutical
- Developer Astellas Pharma; Kotobuki Pharmaceutical; MSD KK; Seoul National University Hospital
- Class Antihyperglycaemics; Glucosides; Small molecules; Thiophenes
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 31 Aug 2022 Astellas Pharma in a collaboration with Seoul National University Bundang Hospital completes a phase III trial in Type-2 diabetes mellitus (Adjunctive treatment) in South Korea (PO) (NCT03076112)
- 08 Sep 2021 Discontinued - Phase-II for Type 2 diabetes mellitus in India (PO) (Astellas pipeline, September 2021)
- 08 Sep 2021 Discontinued - Phase-II for Type 2 diabetes mellitus in Philippines (PO) (Astellas pipeline, September 2021)